Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-17, Stock:NVS, The news for the past five days is as follows:
2018-12-10: NEWS1: Sandoz, Pear Receive FDA Clearance For ReSET-O To Treat Opioid Use Disorder.NEWS2: Sandoz, Pear Receive FDA Clearance For ReSET-O To Treat Opioid Use Disorder.NEWS3: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS4: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS5: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.
2018-12-11: NEWS1: Teva (TEVA) Stock Poised to Record Big Gains in 2019?.NEWS2: Teva (TEVA) Stock Poised to Record Big Gains in 2019?.NEWS3: Teva (TEVA) Stock Poised to Record Big Gains in 2019?.NEWS4: Health Care Sector Update for 12/11/2018: ENTX, AMGN, ITCI, NVS, JNJ, PFE, MRK, ABT.NEWS5: Health Care Sector Update for 12/11/2018: ENTX, AMGN, ITCI, NVS, JNJ, PFE, MRK, ABT.NEWS6: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings.NEWS7: Here is What Hedge Funds Think About Novartis AG (NVS).
2018-12-12: NEWS1: J&J says its psoriasis drug superior to Novartis treatment in study.NEWS2: J&J says its psoriasis drug superior to Novartis' in study.
2018-12-13: NEWS1: J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study.NEWS2: J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study.NEWS3: J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study.NEWS4: Pre-Market Most Active for Dec 13, 2018 :  GE, LPL, KEP, NVS, ERIC, SQQQ, QD, PKX, AMD, MRNS, QQQ, TQQQ.NEWS5: Pre-Market Most Active for Dec 13, 2018 :  GE, LPL, KEP, NVS, ERIC, SQQQ, QD, PKX, AMD, MRNS, QQQ, TQQQ.NEWS6: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen.NEWS7: Novartis Reports EC Approval Of Xolair Syringe For Self-administration.NEWS8: Novartis Reports EC Approval Of Xolair Syringe For Self-administration.
2018-12-14: NEWS1: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS2: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS3: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS4: Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus.NEWS5: Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Novartis.

Answer: Decrease